解析慢性淋巴细胞白血病中依鲁替尼耐药性 - Suppr

Suppr

超能文献

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

作者信息

Lenz Georg

机构信息

Georg Lenz, University Hospital Münster and Cells in Motion, Münster, Germany.

出版信息

J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14.

DOI:10.1200/JCO.2016.72.0102

PMID:28291389

Abstract

摘要

相似文献

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.解析慢性淋巴细胞白血病中依鲁替尼耐药性

J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14.

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?BTK 和 PLCG2 突变是否是慢性淋巴细胞白血病对伊布替尼耐药的必要和充分条件？

Expert Rev Hematol. 2018 Mar;11(3):185-194. doi: 10.1080/17474086.2018.1435268. Epub 2018 Feb 12.

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.在接受依鲁替尼治疗的慢性淋巴细胞白血病中，PLCG2 C2结构域突变与BTK及PLCG2耐药突变同时出现。

Leukemia. 2017 Jul;31(7):1645-1647. doi: 10.1038/leu.2017.110. Epub 2017 Apr 3.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.伊布替尼的布鲁顿酪氨酸激酶抑制剂耐药机制。

N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.

Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.初治的慢性淋巴细胞白血病不存在与治疗耐药相关的布鲁顿酪氨酸激酶突变。

Blood. 2014 Dec 11;124(25):3831-3. doi: 10.1182/blood-2014-08-592725.

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂耐药机制的研究进展。

Int J Mol Sci. 2024 May 11;25(10):5246. doi: 10.3390/ijms25105246.

Targeted therapies: ibrutinib resonates with us.靶向疗法：依鲁替尼引起了我们的共鸣。

Nat Rev Clin Oncol. 2014 Jul;11(7):380. doi: 10.1038/nrclinonc.2014.105. Epub 2014 Jun 17.

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.在依鲁替尼耐药的慢性淋巴细胞白血病中获得的磷脂酶Cγ2的超形态突变赋予B细胞受体激活对布鲁顿酪氨酸激酶的独立性。

Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13.

BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶介导的慢性淋巴细胞白血病对依鲁替尼的耐药性

J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.

Ibrutinib resistance in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的依鲁替尼耐药性。

N Engl J Med. 2014 Jun 12;370(24):2352-4. doi: 10.1056/NEJMc1402716. Epub 2014 May 28.

引用本文的文献

Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.布鲁顿酪氨酸激酶抑制剂：癌症、自身免疫性疾病和多发性硬化症B细胞靶向治疗的新前沿

J Clin Med. 2022 Oct 18;11(20):6139. doi: 10.3390/jcm11206139.

Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs).肿瘤细胞特异性伊布替尼靶向：引入静电抗体-抑制剂偶联物（AiCs）。

Angew Chem Int Ed Engl. 2022 Jan 3;61(1):e202109769. doi: 10.1002/anie.202109769. Epub 2021 Nov 25.

CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.B细胞慢性淋巴细胞白血病细胞中CXCR4和BCR触发的整合素激活依赖于JAK2激活的布鲁顿酪氨酸激酶。

Oncotarget. 2018 Oct 12;9(80):35123-35140. doi: 10.18632/oncotarget.26212.

MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.MALT1抑制在初治和依鲁替尼耐药的慢性淋巴细胞白血病中均有效。

Cancer Res. 2017 Dec 15;77(24):7038-7048. doi: 10.1158/0008-5472.CAN-17-2485. Epub 2017 Oct 9.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验